Effectiveness of first and second boost COVID-19 vaccination in healthy adults during BA.5.2/BF.7 surge in China

References

• Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, Al-Khatib HA, Smatti MK, Coyle P, Al-Kanaani Z, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl J Med. 2022;387(1):21–8. doi:10.1056/NEJMoa2203965.
   PubMed Web of Science ®Google Scholar
• Accorsi EK, Britton A, Shang N, Fleming-Dutra KE, Link-Gelles R, Smith ZR, Derado G, Miller J, Schrag SJ, Verani JR, et al. Effectiveness of homologous and heterologous covid-19 boosters against Omicron. N Engl J Med. 2022;386(25):2433–5. doi:10.1056/NEJMc2203165.
   PubMed Web of Science ®Google Scholar
• Gray G, Collie S, Goga A, Garrett N, Champion J, Seocharan I, Bamford L, Moultrie H, Bekker L-G. Effectiveness of Ad26.COV2.S and BNT162b2 vaccines against Omicron variant in South Africa. N Engl J Med. 2022;386(23):2243–5. doi:10.1056/NEJMc2202061.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O’Connell A-M, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–46. doi:10.1056/NEJMoa2119451.
   PubMed Web of Science ®Google Scholar
• Cerqueira-Silva T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, Júnior JB, Paixão ES, Robertson C, Penna GO, Werneck GL, Barreto ML, et al. Vaccine effectiveness of heterologous coronaVac plus BNT162b2 in Brazil. Nat Med. 2022;28(4):838–43. doi:10.1038/s41591-022-01701-w.
   PubMed Web of Science ®Google Scholar
• Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, Sunny SK, Moore Z. Effectiveness of bivalent boosters against severe Omicron infection. N Engl J Med. 2023;388(8):764–6. doi:10.1056/NEJMc2215471.
   PubMed Web of Science ®Google Scholar
• Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nat Med. 2022;28(9):1933–43. doi:10.1038/s41591-022-01887-z.
   PubMed Web of Science ®Google Scholar
• McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, Wu P, Leung GM, Cowling BJ. Vaccine effectiveness of one, two, and three doses of BNT162b2 and coronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022;22(10):1435–43. doi:10.1016/S1473-3099(22)00345-0.
   PubMed Web of Science ®Google Scholar
• Wei Y, Jia KM, Zhao S, Hung CT, Mok CKP, Poon PKM, Man Leung EY, Wang MH, Yam CHK, Chow TY, et al. Estimation of vaccine effectiveness of coronaVac and BNT162b2 against severe outcomes over time among patients with SARS-CoV-2 Omicron. JAMA Netw Open. 2023;6(2):e2254777. doi:10.1001/jamanetworkopen.2022.54777.
   PubMed Web of Science ®Google Scholar
• Notification on the issuance of the implementation plan for the second booster of COVID-19 vaccine Immunization: National health commission of China. 2022 [accessed 2023 Mar 30]. http://www.gov.cn/xinwen/2022-12/14/content_5731899.htm.
   Google Scholar
• Zhu F, Zhuang C, Chu K, Zhang L, Zhao H, Huang S, Su Y, Lin H, Yang C, Jiang H, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med. 2022;10(8):749–60. doi:10.1016/S2213-2600(22)00131-X.
   PubMed Web of Science ®Google Scholar
• Li J-X, Hou L-H, Gou J-B, Yin Z-D, Wu S-P, Wang F-Z, Zhang Z, Peng Z-H, Zhu T, Shen H-B, et al. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCov after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial. Lancet Infect Dis. 2023. (Online First). doi:10.1016/S1473-3099(23)00350-X.
   Web of Science ®Google Scholar
• Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, He P, Girsang RT, Vergara H, Akram J, et al. Efficacy and safety of the RBD-Dimer–based covid-19 vaccine ZF2001 in adults. N Engl J Med. 2022;386(22):2097–111. doi:10.1056/NEJMoa2202261.
   PubMed Web of Science ®Google Scholar
• Wang XY, Mahmood SF, Jin F, Cheah WK, Ahmad M, Sohail MA, Ahmad W, Suppan VK, Sayeed MA, Luxmi S, et al. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. Emerg Microbes Infect. 2022;11(1):1910–19. doi:10.1080/22221751.2022.2088406.
   PubMed Web of Science ®Google Scholar
• Meng FY, Gao F, Jia SY, Wu X-H, Li J-X, Guo X-L, Zhang J-L, Cui B-P, Wu Z-M, Wei M-W, et al. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Sig Transduct Target Ther. 2021;6(1):271. doi:10.1038/s41392-021-00692-3.
   PubMed Web of Science ®Google Scholar
• Bravo L, Smolenov I, Han HH, Li P, Hosain R, Rockhold F, Clemens SAC, Roa C, Borja-Tabora C, Quinsaat A, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2022;399(10323):461–72. doi:10.1016/S0140-6736(22)00055-1.
   PubMed Web of Science ®Google Scholar
• Hannawi S, Saifeldin L, Abuquta A, Alamadi A, Mahmoud SA, Li J, Chen Y, Xie L. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial. J Infect. 2023;86(2):154–225. doi:10.1016/j.jinf.2022.12.003.
   PubMed Web of Science ®Google Scholar
• Ou S, Huang Z, Lan M, Ye J, Chen J, Guo H, Xiao J, Zhuang S, Wu J, Yang C, et al. The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: an observational study. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.1027924.
   Web of Science ®Google Scholar
• Notice on the issuance of the diagnosis and treatment protocol for COVID-19 (trial version 9): National health commission of the people’s republic of China. 2022. http://www.gov.cn/zhengce/zhengceku/2022-03/15/content_5679257.htm.
   Google Scholar
• Wan X, Lu X. Diagnostics. 9th ed. Beijing, China: People’s Medical Publishing House; 2018.
   Google Scholar
• Shu Y, McCauley J. GISAID: global initiative on sharing all influenza data - from vision to reality. Euro Surveill. 2017;22(13). doi:10.2807/1560-7917.ES.2017.22.13.30494.
   Google Scholar
• Coronavirus pandemic (COVID-19) [Internet]. OurWorldindata.Org. 2020. https://ourworldindata.org/coronavirus.
   Google Scholar
• Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes CDFR, Lind ML, Torres MSS, Tsuha DH, David LCS, Said RFC, et al. Effectiveness of an inactivated covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nat Commun. 2022;13(1):5536. doi:10.1038/s41467-022-33169-0.
   PubMed Web of Science ®Google Scholar
• Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, Júnior JB, Penna GO, Werneck GL, Pearce N, Barreto ML, Boaventura VS, Barral-Netto M, et al. Duration of protection of coronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. Nat Commun. 2022;13(1):4154. doi:10.1038/s41467-022-31839-7.
   PubMed Web of Science ®Google Scholar